Bio-Tech
World’s Most Productive Companies
Bio-Tech
Bio-Tech companies develop novel therapeutics and platform technologies, often well ahead of commercial-scale revenue. Productivity is volatile and pipeline-driven, swinging with clinical milestones, launch timing, and the heavy research investment that precedes payback. The group sits at the bottom of Life Sciences, where pre-commercial spending and uneven revenue weigh on near-term output even as the underlying science advances.
The group had a strong 2025, finishing about 19% below its 2019 baseline. No company in the group reached the 2026 World’s Most Productive Companies list this year. Gains were broad across the group.
Productivity Snapshot
- Bio-Tech ranks eighth of eight Life Sciences peer groups in 2025, at an Industrial Productivity Index of 0.81, about 19% below its 2019 baseline.
- 6 of 9 companies grew productivity in 2025.
- No company in the group earned a place on the 2026 World’s Most Productive Companies list this year.
- Six of nine companies improved in 2025, but the group remains well below its 2019 baseline as research investment continues to run ahead of revenue.
Interested in learning more about how you stack up, where to improve, and the impact on margin, cash, inventory, and assets?